Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill for Reportable Segments

The table below presents goodwill for the Company as of December 31, 2022 (in thousands):

	Total
Balance at December 31, 2021	$	1,066,709
Goodwill impairment during the year		(56,171	)
Balance at December 31, 2022	$	1,010,538

Amortizable Intangible Assets

Intangible assets as of December 31, 2022 and 2021 consisted of the following (in thousands):

	As of December 31,
	2022							2021
	Cost Basis		Accumulated Amortization			Net Book Value		Cost Basis		Accumulated Amortization			Net Book Value
Developed technology (1)	$	4,650,292	$	(2,005,327	)	$	2,644,965	$	4,579,171	$	(1,642,427	)	$	2,936,744
In-process research and development (1)		810,000		—			810,000		880,000		—			880,000
Other intangibles		29,894		(10,082	)		19,812		29,894		(6,520	)		23,374
Total intangible assets	$	5,490,186	$	(2,015,409	)	$	3,474,777	$	5,489,065	$	(1,648,947	)	$	3,840,118

(1)In April 2022, the European Commission issued a legally binding decision based on the favorable recommendation of the CHMP of the EMA to grant a MA for UPLIZNA for the treatment of adult patients with NMOSD in the EU. As a result, the Company transferred $70.0 million of IPR&D to developed technology in the second quarter of 2022. As of December 31, 2022, the remaining IPR&D relating to the Viela acquisition was $810.0 million.

Estimated Future Amortization Expense

As of December 31, 2022, estimated future amortization expense was as follows (in thousands):

2023	$	359,377
2024		359,377
2025		359,377
2026		304,114
2027		253,637
Thereafter		1,028,895
Total	$	2,664,777